IRX 2

Drug Profile

IRX 2

Alternative Names: Citoplurikin; IRX-2

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IRX Therapeutics
  • Developer IRX Therapeutics; Providence Health & Services
  • Class Antineoplastics; Cytokines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I Breast cancer
  • Preclinical Cancer

Most Recent Events

  • 11 Sep 2017 Updated efficacy data from a phase IIa trial in Head and neck cancer released by IRX Therapeutics
  • 28 Aug 2017 University of Southern California and National Cancer Institute plan a phase II trial for Cervical squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neoplasia 3 (Combination therapy) in USA (NCT03267680)
  • 09 Feb 2017 Phase-I clinical trials in Breast cancer (Early-stage disease, Neoadjuvant therapy) in USA (SC) (NCT02950259)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top